文献速递骨软组织肉瘤与黑色素瘤支持与姑息治疗

免疫检查点抑制剂相关脂肪酶升高与1型糖尿病:德国90例多中心研究

Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
PubMed 文献 · Eur J Cancer · 2021-03-31

该回顾性多中心研究收集了14家德国皮肤肿瘤中心接受ICI治疗后新发脂肪酶升高(≥2倍正常上限)或新诊断1型糖尿病的皮肤癌患者。68例脂肪酶升高患者中仅22%有胰腺炎症状,73%合并其他irAE;22例新发1型糖尿病中55%伴脂肪酶升高,常快速起病伴酮症酸中毒。结论认为脂肪酶升高常非胰腺炎所致,或仅需监测血糖。

要点

  • ICI相关脂肪酶升高多无症状,仅22%符合胰腺炎表现。
  • 脂肪酶升高常合并其他irAE,以结肠炎最常见。
  • 新发1型糖尿病常伴脂肪酶升高,起病急、易酮症酸中毒。

核心结论

  • ICI治疗期间血清脂肪酶升高常与胰腺炎无关,可能由其他irAE引起。
  • 仅需常规监测血糖,出现胰腺炎或外分泌功能不全症状时才进一步检查。

研究设计与样本

  • 回顾性多中心研究,收集14家德国皮肤肿瘤中心接受ICI治疗后新发脂肪酶升高或新诊断1型糖尿病的皮肤癌患者。

主要发现

  • 停用ICI(24例,35%)或中断ICI(26例,38%)后脂肪酶下降,但再引入ICI后24例中12例脂肪酶再次升高。
  • 18例(27%)继续ICI不变,其中12例(67%)脂肪酶恢复正常。
  • 22例新诊断ICI相关1型糖尿病中,12例(55%)伴脂肪酶升高,多在糖尿病诊断前后短期出现;14例(64%)合并其他irAE(主要为甲状腺炎)。
  • 1型糖尿病患者常快速起病,伴酮症酸中毒、C肽降低和血糖显著升高。

临床怎么用

  • ICI治疗期间发现脂肪酶升高,应评估胰腺炎症状及外分泌功能,无症状者可能无需停用ICI。
  • 常规监测血糖有助于早期发现ICI相关1型糖尿病,尤其伴脂肪酶升高者。

局限性

  • 回顾性研究,样本量有限,可能存在选择偏倚。
  • 脂肪酶升高的病因未统一系统评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Immune checkpoint inhibition (ICI) triggers immune-related adverse events (irAEs). The relevance of lipase elevation remains unclear. PATIENTS AND METHODS: Skin cancer patients with newly detected serum lipase elevation (at least twofold upper normal limit) or newly diagnosed type I diabetes mellitus upon ICI therapy were retrospectively collected at 14 German skin cancer centres. RESULTS: We identified 68 patients with lipase elevation occurring after a median time of 19 (range 1-181) weeks on ICI, 15 (22%) thereof had symptoms consistent with pancreatitis. Forty-seven patients (73%) had other irAE, mainly colitis. Discontinuation (n = 24, 35%) or interruption (n = 26, 38%) of ICI resulted in decrease of lipase after reinduction of ICI lipase levels increased again in 12 of 24 patients. In 18 patients (27%), ICI was continued unchanged, and in 12 (67%) of them, lipase levels normalised. Twenty-two patients were identified with newly diagnosed type I diabetes mellitus related to ICI, and 12 (55%) thereof had also lipase elevation mainly shortly before or after the diagnosis of diabetes. Fourteen (64%) patients had other irAE, mainly thyroiditis. Irrespective of lipase elevation, patients frequently showed a rapid onset with ketoacidosis, decreased c-peptide, and strongly increased blood glucose levels. CONCLUSION: Increased serum lipase during ICI is often not associated with pancreatitis but with other irAE as possible cause. Therefore, it might be sufficient to regularly monitor blood glucose levels and perform further workup only in case of signs or symptoms of pancreatitis and/or exocrine pancreas insufficiency.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Grimmelmann I, Momma M, Zimmer L, et al. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group. Eur J Cancer. 2021. PMID: 33812141. doi:10.1016/j.ejca.2021.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。